Given a notoriously poor local control in vulvar malignant melanoma (VMM) with recurrence rates of 30-50% vs nearly 3% in cutaneous melanomas, researchers analyzed clinicopathologic characteristics of women suffering from VMM (n=37), following reviewing three decades of clinical follow up data in their institutional databases.
Publications
Frontline BRAF testing–guided treatment for advanced melanoma in the era of immunotherapies: A cost-utility analysis based on long-term survival data
Since the effectiveness of immune checkpoint inhibitors (ICIs) and BRAF and MEK inhibitors have improved advanced melanoma recovery, researchers conducted the study for comparing the cost-utility of these novel agents and their combinations with or without BRAF gene testing guidance for treating newly diagnosed advanced melanoma with unknown BRAF status.
FDA Grants Fast Track Designation to CMP-001 Combination in Advanced Melanoma
The FDA has granted Fast Track designation to CMP-001 in combination with nivolumab (Opdivo) plus ipilimumab (Yervoy), which will undergo clinical trial development both as a potential extender of time to disease relapse as an initial treatment of patients with unresectable stage III or stage IV melanoma, as well as to improve the overall tumor response rate as treatment of patients with unresectable or metastatic melanoma refractory to prior anti-PD-1 blockade.1
Comorbidity burden on receipt of adjuvant immunotherapy and survival in patients with stage III melanoma: an analysis of the National Cancer Database
Researchers used the National Cancer Database to explore the connection between comorbidity burden, receipt of adjuvant immunotherapy, and survival in patients with stage III melanoma.